| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
ProMetic Life Sciences Inc (TSE: PLI)
Â
PLI Technical Analysis
4
| As on 31st Oct 2017 PLI Share Price closed @ 1.37 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.90 & Sell for SHORT-TERM with Stoploss of 1.47 we also expect STOCK to react on Following IMPORTANT LEVELS. |
Â
Â
PLI Share Price
| Open | 1.46 | Change | Price | % |
| High | 1.46 | 1 Day | -0.07 | -4.86 |
| Low | 1.35 | 1 Week | 0.00 | 0.00 |
| Close | 1.37 | 1 Month | -0.27 | -16.46 |
| Volume | 927257 | 1 Year | -1.13 | -45.20 |
| 52 Week High 2.89 | 52 Week Low 1.12 | ||||
Â
TSE Canada Most Active Stocks
| BIN | 41.40 | -1.62% |
| LSG | 2.08 | 8.33% |
| TBE | 0.03 | 0.00% |
| ECA | 15.09 | 4.43% |
| SC | 60.83 | -0.44% |
| PRE | 0.64 | 0.00% |
| ELD | 1.62 | -6.90% |
| MFC | 25.94 | -0.04% |
| CPG | 10.61 | 4.53% |
| BBD-B | 2.73 | -1.09% |
Â
TSE Canada Top Gainers Stocks
Â
TSE Canada Top Losers Stocks
Â
Â
| PLI Daily Charts |
PLI Intraday Charts |
Whats New @ Bazaartrend |
PLI Free Analysis |
|
|
Â
PLI Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 1.47 |
| RESISTANCE | 1.43 |
| SUPPORT | 1.31 |
| SUPPORT | 1.27 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
Â
PLI Target for Month April
| 4th UP TARGET | 2.08 |
| 3rd UP TARGET | 1.85 |
| 2nd UP TARGET | 1.71 |
| 1st UP TARGET | 1.57 |
| 1st DOWN TARGET | 1.17 |
| 2nd DOWN TARGET | 1.03 |
| 3rd DOWN TARGET | 0.89 |
| 4th DOWN TARGET | 0.66 |
Â
PLI Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
Â
PLI Target for Year 2021
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
Â
ProMetic Life Sciences Inc ( TSE Canada Symbol : PLI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
Â
PLI Other Details
| Segment | EQ | |
| Market Capital | 0.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | > | |
Â
PLI Address
 |
531 Des Prairies Boulevard Building 15 Laval, QC H7V 1B7 Canada Phone: 450-781-0115 Fax: 450-781-4477 |
|
Â
PLI Latest News
Â
Â
PLI Business Profile
ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparation, plasma-derived therapeutics, and small-molecule drugs. The company also offers its technologies for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutics products targeting unmet medical needs in the fields of fibrosis, anemia, cancer, and autoimmune disease, as well as plasma-derived therapeutics in orphan drug indications. It operates in two segments, Therapeutics and Protein Technology. The Therapeutics segmentÂ’s lead product includes PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. This segment also develops PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases; and PBI-1402, a drug candidate for the treatment of anemia indications. The Protein Technology segment provides plasma protein purification system, a solution for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology for various biopharmaceutical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.
Â
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
